The Association of Southeast Asian Nations (ASEAN) Member States, comprising Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam, convened in a two-day online workshop to ensure fair prices and effective financing of medicines and health technologies with the aim to fortify health systems and to achieve wider Universal Health Coverage on April 6-7, 2022.
The Department of Health (DOH) on March 30, 2022 convened patient groups and civil society organizations (CSOs) to discuss updates on the national government’s COVID-19 response, vaccination program rollout, and the ongoing initiatives to provide Filipinos better access to pharmaceutical commodities and healthcare services during the virtual 15th Policy Dialogue on Universal Health Care (UHC) and Access to Medicines with theme “Gamot Para sa Lahat, Siguruhing Sasapat”.
The Department of Health (DOH) announces the full implementation of drug price caps starting March 23, 2022 through Executive Order (EO) No. 155 signed by President Rodrigo Duterte. This brings the total number of drugs with maximum drug retail price to 121 molecules or 204 drug formulas, following the first round of price regulation implemented in June 2020 with the signing of EO No. 104 which covered 87 molecules.
The Executive Order (EO) No. 155, “Further Improving Access to Healthcare Through the Regulation of Prices in the Retail of Drugs and Medicines,” which was issued by President Rodrigo R. Duterte on 07 December 2021, subjected 34 drug molecules or 71 drug formulas under price regulation through Maximum Wholesale Price (MWP) and Maximum Retail Price (MRP). The implementation shall begin on 23 March 2022.
Patient Recruitment and Referral for the World Health Organization (WHO) COVID-19 Solidarity Therapeutic Trial Plus
DOH request its NCR hospitals to facilitate patient recruitment for clinical trial.
Advisory on changes in the 2nd Batch of the 2022 Antimicrobial Stewardship (AMS) Blended Learning Program for Hospitals
DOH informs stakeholders on the change in schedule of the Batch 2 AMS Blended Learning Program for Hospitals
Updated Suggested Retail Price (SRPs) for Emergency Essential Medicines due to the Coronavirus Disease 2019 (COVID-19) Health Event as of April 22, 2022
DOH adds Molnupiravir (400 mg) in the Updated SRP List
Signed Endorsement Letters for the Updated List of Vat-Exempt Medicines Under Republic Act 11534 known as Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act
The Food and Drug Administration (FDA) endorses to the Bureau of Internal Revenue (BIR) the updated list of VAT-Exempt Medicines (as of March 2022) under RA 11354, otherwise known as the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act.
Updated Suggested Retail Price (SRPs) for Emergency Essential Medicines and Medical Devices due to the Coronavirus Disease 2019 (COVID-19) Health Event as of January 19, 2022
DOH adds Molnupiravir in the Updated SRP List
Adjustments in Maximum Retail Price (MRP) Regulation of Certain Medicines that are Covered by Executive Order No. 155 Pursuant to Exemption from Value Added Tax (VAT)
DOH informs the public of the adjustments in the Maximum Retail Price (MRP) of certain medicines that are covered by EO 155
Telephone Number: 02-8757734 Loc. 253
Address: 4th Floor, Philippine Blood Center, Lung Center Compound, Quezon Avenue, Quezon City
Email Address: firstname.lastname@example.org